Revelation Biosciences Inc. Warrant (REVBW)
$0.01
As on 08-Sep-2026 14:35EDT
Market cap
--
Revenue (TTM)
--
P/E Ratio
--
P/B Ratio
--
Div. Yield
--
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
--
-
ROE
--
-
ROCE
--
-
Industry P/E
--
-
EV/EBITDA
--
-
Debt to Equity
--
-
Book Value
--
-
EPS
--
-
Face value
--
-
Shares outstanding
--
5 Years Aggregate
CFO
$-29.81 Mln
EBITDA
$-31.55 Mln
Net Profit
$-23.04 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Revelation Biosciences Inc. Warrant (REVBW)
| 17.5 | -4.1 | -6.9 | -34.7 | -15.5 | -- | -- |
|
BSE Sensex*
| -11.7 | -4.8 | 1.1 | -8.2 | 3.9 | 5.1 | 10.0 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
|---|---|---|---|
|
Revelation Biosciences Inc. Warrant (REVBW)
| 14.3 | -33.7 | -19.1 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Revelation Biosciences Inc. Warrant (REVBW)
Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform... of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory response. It also engages in the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California. Read more
-
CEO & Director
Mr. James M. Rolke
-
CEO & Director
Mr. James M. Rolke
-
Headquarters
San Diego, CA
-
Website
FAQs for Revelation Biosciences Inc. Warrant (REVBW)
What is the current share price of Revelation Biosciences Inc Warrant (REVBW) Today?
The share price of Revelation Biosciences Inc Warrant (REVBW) is $0.01 (NASDAQ) as of 08-Sep-2026 14:35 EDT. Revelation Biosciences Inc Warrant (REVBW) has given a return of -15.54% in the last 3 years.
What is the current PB & PE ratio of Revelation Biosciences Inc Warrant (REVBW)?
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
0.00 |
0.00 |
2024 |
0.00 |
0.00 |
2023 |
0.00 |
0.00 |
2022 |
0.00 |
0.00 |
2021 |
-- |
-- |
What is the 52 Week High and Low of Revelation Biosciences Inc Warrant (REVBW)?
The 52-week high and low of Revelation Biosciences Inc Warrant (REVBW) are Rs 0.02 and Rs 0.01 as of 11-Sep-2026.
What is the market cap of Revelation Biosciences Inc Warrant (REVBW)?
Revelation Biosciences Inc Warrant (REVBW) has a market capitalisation of -- as on 24-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Revelation Biosciences Inc Warrant (REVBW)?
Before investing in Revelation Biosciences Inc Warrant (REVBW), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.